The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

@article{Park2016TheHI,
  title={The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.},
  author={K Park and Bora Oh and Mi-hee Lee and Ky-Youb Nam and Hae Ran Jin and Hannah Yang and Junyoung Choi and S Kim and Dae Ho Lee},
  journal={Cancer letters},
  year={2016},
  volume={372 1},
  pages={75-81}
}
RAS-driven tumors are often difficult to treat with conventional therapies and therefore, novel treatment strategies are necessary. The present study describes a promising targeted therapeutic strategy against non-small cell lung cancer (NSCLC) harboring KRAS mutations, which has intrinsic resistance to MEK inhibition. Results showed that intrinsic resistance to MEK inhibition occurred via high AKT expression by PI3K activation as a bypass pathway. The HSP90 inhibitor AUY922 suppressed PI3K-AKT… CONTINUE READING